List of medicinal products under additional monitoring

Developing cancer medicines for children

EMEA-003576-PIP01-24

EMEA-003574-PIP01-24

Opinion/decision on a Paediatric investigation plan (PIP): Recarbrio, imipenem monohydrate,cilastatin sodium,relebactam (MK-7655A), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0190/2024

EMEA-002489-PIP02-24

Opinion/decision on a Paediatric investigation plan (PIP): Steglatro, Ertugliflozin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0189/2024

EMEA-000534-PIP03-17-M01

Q&A clinic on web-based electronic Application Form (eAF) functionalities for CAPs and non-CAPs variations, Online, European Medicines Agency, Amsterdam, the Netherlands, from 8 July 2025, 10:00 (CEST) to 8 July 2025, 11:00 (CEST)

Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Date of authorisation: 18/10/2009, Revision: 14, Status: Authorised